Abstracts tagged "risk factors"

Abstract Number: 1642 • ACR Convergence 2021
Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy
Roberta Berard¹, Michael Rieder², Erkan Demirkaya², Michael Miller³ and Renee Pang², ¹London Health Sciences Centre, London, ON, Canada, ²University of Western Ontario, London, ON, Canada, ³University of Western Ontario, Children's Research Institute, London, ON, Canada
Background/Purpose: Prednisone is a glucocorticoid (GC) medication commonly used in moderate ( >7.5 mg per day) to high doses (≥ 1 mg/kg/day) for children with…
Abstract Number: 0383 • ACR Convergence 2021
Differences Between Male vs. Female Presenting with Back Pain in an Integrated Delivery System
Aniket Kawatkar¹, Esther Yi², Erika Estrada¹, Jose Pio¹, Cecilia Portugal¹, David Yi¹ and Steve Lee³, ¹Kaiser Permanente Southern California, Pasadena, CA, ²Novartis Pharmaceuticals Corporation, Weehawken, NJ, ³Southern California Permanente Medical Group, Fontana, CA
Background/Purpose: Back pain exerts significant economic burden and in its inflammatory form is the main clinical symptom of axial spondylarthritis. We evaluated differences in patient…
Abstract Number: 0897 • ACR Convergence 2021
Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Tae-Han Lee¹, Bon San Koo², Bora Nam³, Seunghun Lee⁴, Kyung Bin Joo⁴ and Tae-Hwan Kim³, ¹Keimyung University Dongsan Hospital, Daegu, Republic of Korea, ²Inje University Seoul Paik Hospital, Seoul, Republic of Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Hanyang University Hospital, Seoul, Republic of Korea
Background/Purpose: Previous studies investigating the course of spinal structural progression in patients with ankylosing spondylitis (AS) using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)…
Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Benjamin Worcester¹, Dorothy Wang², Susan Morton³ and Michelle Leech⁴, ¹Monash Health, Melbourne, Australia, ²Melbourne Health, Clayton, Australia, ³Monash Health, Clayton, Australia, ⁴Monash Medical Centre, Australia, Australia
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
Abstract Number: 0413 • ACR Convergence 2021
Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort
Jessica Kapralik, Robert Morton, Malik Farooqi, Karen Beattie, Nathan Hambly and Maggie Larche, McMaster University, Hamilton, ON, Canada
Background/Purpose: In patients with SSc, interstitial lung disease (SSc-ILD) and pulmonary hypertension affect 50-70% of patients and are the leading cause of death. Recent trials…
Abstract Number: 0980 • ACR Convergence 2021
Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein-associated enzyme with paraoxonase, lactonase, and arylesterase activities.1 PON1 gene polymorphisms at the Q192R allele (rs662) have been associated…
Abstract Number: 1748 • ACR Convergence 2021
The Peroxisome Proliferator-Activated Receptor-γ (PPAR) Agonist Pioglitazone Improves Vascular and Metabolic Dysfunction in Patients with Systemic Lupus Erythematosus (SLE)
Sarfaraz Hasni¹, Yenealem Temesgen-Oyelakin², Michael Davis³, Sarthak Gupta⁴, Elaine Poncio⁵, Mohammad Naqi¹, Xinghao Wang⁶, Christopher Oliveira⁷, Dillon Claybaugh¹, Amit Dey¹, Shajia Lu¹, Philip Carlucci⁸, Zerai Manna¹, Yinghui Shi¹, Isabel Ochoa⁵, Donald Thomas⁹, Theo Heller¹⁰, Massimo Gadina¹¹, Jun Chu⁴, Monica Purmalek¹, Xiaobai Li¹², Martin Playford¹³, Nehal Mehta¹³ and Mariana Kaplan¹, ¹National Institutes of Health, Bethesda, MD, ²National Institutes of Health (NIH), Bethesda, MD, ³NIAMS, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵NIH/NIAMS, Bethesda, MD, ⁶NIAMS/NIH, Bethesda, MD, ⁷National Institutes of Health (NIH), Vienna, VA, ⁸New York University School of Medicine, New York, NY, ⁹Arthritis and Pain Associates of Prince George's County, Silver Spring, MD, ¹⁰NIDDK/National Institutes of Health, Bethesda, MD, ¹¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ¹²Clinical Center, National Institutes of Health, Bethesda, MD, ¹³NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Premature cardiovascular events in SLE are associated with significant mortality and morbidity with no effective treatments described to date. Both immune dysregulation characteristics of…
Abstract Number: 0518 • ACR Convergence 2021
Predicted Expression of Genes Involved in the Thiopurine Metabolic Pathway Is Associated with Azathioprine Discontinuation Due to Bone Marrow Toxicity
Laura Daniel¹, Alyson Dickson², Jacy Zanussi², Tyne Miller-Fleming², Peter Straub², Wei-Qi Wei², Dale Plummer², William Dupont³, Ge Liu², Prathima Anandi², Tyler Reese², Kelly Birdwell², Vivian Kawai⁴, Adriana Hung², Nancy J. Cox², Qiping Feng², C. Michael Stein² and Cecilia Chung², ¹Vanderbilt University Medical Center, Pegram, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Azathioprine is a thiopurine used to treat inflammatory conditions; however, it is often discontinued due to dose-dependent bone marrow toxicity. The Pharmacogenomics Knowledgebase (PharmGKB)…
Abstract Number: 1052 • ACR Convergence 2021
Female Reproductive Factors and Risk of Joint Replacement Arthroplasty of the Knee and Hip Due to Osteoarthritis in Postmenopausal Women: A Nationwide Cohort Study of 1.36 Million Women
Yeonghee Eun¹, Jung Eun Yoo², Kyungdo Han³, Dahye Kim³, Jaejoon Lee¹, Dong-Yun Lee¹, Dae-Hee Lee¹, Dong Wook Shin¹ and Hyungjin Kim¹, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Republic of Korea, ³Soongsil University, Seoul, Republic of Korea
Background/Purpose: Previous studies of the relationships between female reproductive factors and osteoarthritis (OA) have shown conflicting results. In this study, we aimed to explore the…
Abstract Number: 1800 • ACR Convergence 2021
Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
Ananta Paine¹, Paul Brookes², Dongmei Li³, Somyaroop Bhattacharya⁴, Maria de la Luz Garcia-Hernandez¹ and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²Department of Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, ³Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, ⁴Division of Neonatology, Department of Pediatrics, University of Rochester, Rochester, NY
Background/Purpose: The transition to psoriatic arthritis (PsA) occurs in 20-30% of psoriasis (Ps) patients, but the mechanisms underlying the emergence of musculoskeletal disease are not…
Abstract Number: 0017 • ACR Convergence 2021
Lessons Learnt from Associations Between Anti-modified Protein Antibodies and Risk Factors: Human Leukocyte Antigen – Shared Epitope Alleles Solely Associate with Anti-citrullinated Protein Antibodies
Tineke J van wesemael, Annemarie L. Dorjee, Tom WJ Huizinga, Annette H.M van der Helm-van Mil, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of auto-antibodies to post translationally modified proteins (anti-modified protein antibodies (AMPA)): anti-citrullinated protein antibodies (ACPA), anti-carbamylated…
Abstract Number: 0576 • ACR Convergence 2021
Associations of the MUC5B Promoter Variant with Timing of Articular Diagnosis and Interstitial Lung Disease in Rheumatoid Arthritis
Gregory McDermott¹, Ritu Gill², Staci Gagne³, Suzanne Byrne³, Weixing Huang³, Jing Cui⁴, Lauren Prisco⁵, Alessandra Zaccardelli³, Lily Martin³, Nancy Shadick⁶, Paul Dellaripa³, Tracy Doyle⁷ and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham & Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: The common promoter variant of MUC5B (G >T, rs35705950) is associated with increased mucin 5B production in lung parenchyma and is an established genetic…
Abstract Number: 1088 • ACR Convergence 2021
The Association Between Anti-Type Ⅱ Collagen Antibodies at the Time of Diagnosis and Recurrence in Relapsing Polychondritis
Osamu Iri, Keisuke Nishimura, Daisuke Waki, Kohei Yo, Ryuta Inaba, Shintaro Yamamoto, Kaoru Mizukawa, Tomohiro Yoshida, Hiroyuki Murabe and Toshihiko Yokota, Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan
Background/Purpose: Serum titers of anti-type Ⅱ collagen (anti-CⅡ) antibodies were reported to rise at the recurrence of relapsing polychondritis (RP). It remains to be identified…
Abstract Number: 0071 • ACR Convergence 2021
Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Gustavo Balbi¹, Yasaman Ahmadzadeh², Maria Tektonidou³, Vittorio Pengo⁴, Savino Sciascia⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul R Fortin⁹, Chary lopez-pedrera¹⁰, Lanlan Ji¹¹, Tatsuya Atsumi¹², Hannah Cohen¹³, Guilherme Ramires de Jesus¹⁴, D. Ware Branch¹⁵, Cecilia Nalli¹⁶, Nina Kello¹⁷, Michelle Petri¹⁸, Esther Rodriguez-Almaraz¹⁹, Giuseppe Barilaro²⁰, Jason Knight²¹, Bahar Artim-Esen²², Rohan Willis²³, Maria Laura Bertolaccini²⁴, Robert Roubey²⁵, Doruk Erkan², Danieli De Andrade¹ and on Behalf of APS ACTION², ¹University of São Paulo, São Paulo, Brazil, ²Hospital for Special Surgery, New York, NY, ³FORZAFORTE HELLAS LTD, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵University of Turin, Turin, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸University of Milan, Milan, Italy, ⁹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Hokkaido University, Sapporo, Japan, ¹³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah, Salt Lake City, UT, ¹⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁷Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Clínic Barcelona - Hospital Universitari, Barcelona, Spain, ²¹University of Michigan, Ann Arbor, MI, ²²Istanbul University School of Medicine, İstanbul, Turkey, ²³University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵University of North Carolina, Chapel Hill, NC
Background/Purpose: Damage Index in APS (DIAPS) is a scoring system developed to assess long-term damage in thrombotic primary antiphospholipid syndrome (PAPS), which also correlates with…
Abstract Number: 0578 • ACR Convergence 2021
Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years
Natalie McCormick¹, Chio Yokose², Na Lu³, Amit Joshi¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and the metabolic (insulin resistance) syndrome frequently coexist. Intravenous insulin has been shown to raise serum urate (SU) levels in physiologic studies1 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.